{
  "docId": "019de072-afcf-751b-be79-65bbe03fb0c7",
  "docSlug": "a4681640730b4446aa1f6ee077b8a572",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 23 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 23,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "Includes comparative data against FOLFOX and TOPAZ-1.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/15",
  "deckHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7",
  "deckJsonHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json",
  "deckAnchorHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.95,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "list",
      "text": "24 patients with BTC have been enrolled and dosed\n10 partial responses (PRs) for a 42% ORR in patients treated in the second- and third-line settings (54% of patient were treated in the 3rd line setting)\nOther regimens in BTC:\nFOLFOX (NCCN guidelines): 5% ORR in the second-line setting\nTOPAZ-1 (Phase 3 development): 26.7% ORR for Gem/Cis/Durvalumab (anti-PD-L1) in the first-line setting\nMedian time on study approximately 6 months, with 7 patients ongoing\nAdverse event profile similar to Phase 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0740b872-6278-41ee-afe5-99b5973903b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.02,
        "y": 0.14
      },
      "kind": "title",
      "text": "CTX-009 Interim Phase 2 Study Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce3d0c70-ede7-4672-b085-fc772710a3dc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "4eeff147-fa1c-4fa6-a837-389572a81191",
      "evidence": "list/bullet: 24 patients with BTC have been enrolled and dosed",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667",
      "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company",
      "position": 0,
      "objective": "Highlight the potential consequences of not investing in Compass Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}